Merck Can Still Offer Healthy Doses Of Profits, Despite Disappointing Results
Wall Street Playbook • Tue, Oct. 28
- Merck is still making money, despite the revenue miss.
- With a yield of 3.10% and having just been granted approval for a key drug by the FDA, now is the wrong time to lose faith.
- The best play here is to add to an existing long position and wait for Merck to complete its transformation.